secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harvard Apparatus Regenerative Technology, Inc. (HRGN)
CIK:        0001563665
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001563665-22-000010
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biostage reports Q3 net loss of $1.1M ($0.10/share); cash runway into Q2 2023
-----------------------------------------------------------------------------

- Net loss $1.1M for Q3 2022 vs $0.8M in Q3 2021; EPS -$0.10 vs -$0.08.
- Operating cash $3.0M as of Sept 30, 2022; cash used in ops $3.4M in first 9 months.
- Expects cash to fund operations into Q2 2023.
- Received U.S. patent for cellularized patch-based scaffolds (Biostage Tissue Patch) on Oct 25, 2022.
- Appointed Joseph Damasio as CFO on Aug 8, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563665/000156366522000010/0001563665-22-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563665/000156366522000010/tmb-20221114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001563665-22-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer